Morepen Labs.

Why is Morepen Laboratories Ltd falling/rising?

As of 03-Aug, Morepen Laboratories Ltd's stock price is currently rising at 57.68, reflecting short-term gains despite long-term concerns such as a 2.22% decline over the past month and a significant drop in profits. Investor participation is also declining, indicating potential challenges ahead for the company's financial health.

As of 03-Aug, Morepen Laboratories Ltd's stock price is rising, currently at 57.68, reflecting a change of 0.68 (1.19%) upward. The stock has outperformed its sector by 0.76% today and has been on a consecutive gain for the last two days, accumulating a total return of 2.12% during this period. Additionally, the stock's current price is higher than its 5-day, 50-day, 100-day, and 200-day moving averages, indicating a positive short-term trend.<BR><BR>However, it is important to note that while the stock is experiencing a rise in the short term, there are underlying factors that suggest caution. The stock has shown a decline of 2.22% over the past month, and its year-to-date performance is strong at +40.44%, contrasting with the Sensex's -7.72%. Despite this, the stock has generated a return of -0.14% over the past year, and its profits have decreased by 39.3%, indicating potential long-term challenges.<BR><BR>Investor participation has also been declining, with delivery volume falling by 47.3% against the 5-day average, which could signal reduced confidence among investors. Furthermore, the company's financial health is concerning, with a low return on capital employed (ROCE) of 7.60% and a debt-to-equity ratio of 0.02, suggesting limited leverage and growth potential. <BR><BR>In summary, while Morepen Laboratories Ltd is currently rising in price due to short-term gains and positive performance metrics, there are significant long-term concerns that could affect its sustainability in the market.

Which are the latest news on Morepen Labs.?

Should I buy, sell or hold Morepen Laboratories Ltd?

When is the next results date for Morepen Laboratories Ltd?

The next results date for Morepen Laboratories Ltd is August 4, 2026.

The next results date for Morepen Laboratories Ltd is scheduled for August 4, 2026.

How big is Morepen Labs.?

As of 10th June, Morepen Laboratories Ltd has a market capitalization of 2,685.00 Cr, with net sales of 1,805.70 Cr and a net profit of 94.87 Cr reported in the latest four quarters.

As of 10th June, Morepen Laboratories Ltd has a market capitalization of 2,685.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Morepen Labs reported net sales of 1,805.70 Cr and a net profit of 94.87 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 1,156.23 Cr and total assets valued at 1,778.10 Cr.

Who are in the management team of Morepen Labs.?

The management team of Morepen Labs includes Sushil Suri (Chairman & Managing Director), Sanjay Suri (Whole-time Director), and several Non-Executive & Independent Directors: Manoj Joshi, Bhupender Raj Wadhwa, Sukhcharan Singh, Praveen Kumar Dutt, and Savita, along with Vipul Kumar Srivatava (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Morepen Labs includes the following key members:<BR><BR>1. **Sushil Suri** - Chairman & Managing Director<BR>2. **Manoj Joshi** - Non-Executive & Independent Director<BR>3. **Bhupender Raj Wadhwa** - Non-Executive & Independent Director<BR>4. **Sukhcharan Singh** - Non-Executive & Independent Director<BR>5. **Vipul Kumar Srivatava** - Company Secretary & Compliance Officer<BR>6. **Sanjay Suri** - Whole-time Director<BR>7. **Praveen Kumar Dutt** - Non-Executive & Independent Director<BR>8. **Savita** - Non-Executive & Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Morepen Labs.?

Peers of Morepen Labs include RPG LifeScience, Unichem Labs, Aarti Drugs, Novartis India, Solara Active, Dishman Carbogen, Kwality Pharma, Venus Remedies, and Hikal. Morepen Labs has average management risk and below average growth, with a 1-year return of -27.44%.

Peers: The peers of Morepen Labs. are RPG LifeScience., Unichem Labs., Aarti Drugs, Novartis India, Solara Active, Dishman Carbogen, Kwality Pharma, Venus Remedies, and Hikal.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience. and Novartis India, while Average management risk is found at Unichem Labs., Aarti Drugs, Morepen Labs., Kwality Pharma, Venus Remedies, and Hikal, and the rest. Below Average management risk is present at Solara Active and Dishman Carbogen. Growth is rated as Good for Unichem Labs., Novartis India, and Venus Remedies, while Below Average growth is noted for RPG LifeScience., Aarti Drugs, Morepen Labs., Kwality Pharma, Hikal, and the rest. Solara Active and Dishman Carbogen exhibit Below Average growth. Capital Structure is rated Excellent for RPG LifeScience., Novartis India, Morepen Labs., Kwality Pharma, and Venus Remedies, while Good is noted for Unichem Labs. and Aarti Drugs, and the rest. Below Average capital structure is observed at Solara Active and Dishman Carbogen.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 268.68%, while Dishman Carbogen has the lowest at -38.27%. Morepen Labs. has a 1-year return of -27.44%, which is higher than Dishman Carbogen's but lower than Venus Remedies'. Additionally, the six-month return is negative for Dishman Carbogen, Solara Active, and Hikal.

What does Morepen Labs. do?

Morepen Laboratories Limited is an Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with recent net sales of 485 Cr and a net profit of 16 Cr as of March 2026. It has a market cap of INR 2,685 Cr and key metrics include a P/E ratio of 38.00 and a dividend yield of 0.41%.

Overview:<BR>Morepen Laboratories Limited is an India-based pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History:<BR>Morepen Laboratories was incorporated in an unspecified year and has maintained its status as a pharmaceutical company. The latest quarterly results reported are for March 2026, showcasing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 485 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 16 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 2,685 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 38.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.41% <BR>Debt-Equity: 0.09 <BR>Return on Equity: 5.75% <BR>Price to Book: 2.14 <BR><BR>Contact Details:<BR>Address: Morepen Village, Nalagarh Road Near Baddi Solan Himachal Pradesh : 173205 <BR>Tel: 91-01795-276201-03 <BR>Email: investors@morepen.com <BR>Website: http://www.morepen.com

Are Morepen Laboratories Ltd latest results good or bad?

Morepen Laboratories Ltd's latest results are concerning, showing a slight increase in net sales but a significant 42.78% drop in net profit and a multi-quarter low operating margin of 5.04%. This indicates serious operational challenges despite record revenue, making the overall performance more negative than positive.

The latest results for Morepen Laboratories Ltd indicate a challenging situation for the company. While the net sales for Q4 FY26 reached ₹484.72 crores, reflecting a slight growth of 0.12% quarter-on-quarter and 4.05% year-on-year, the profitability metrics have significantly deteriorated. <BR><BR>Net profit fell sharply by 42.78% on a quarter-on-quarter basis to ₹15.74 crores, and the operating margin dropped to 5.04%, marking a multi-quarter low. This decline in margins suggests that the company is facing structural cost pressures rather than just temporary challenges. Additionally, the profit after tax (PAT) margin contracted to 3.24%, down from 5.68% in the previous quarter.<BR><BR>A concerning aspect of the financial performance is the increased reliance on non-operating income, which accounted for a substantial portion of the profit before tax. This raises questions about the sustainability of the earnings reported. <BR><BR>Overall, while Morepen achieved record revenue, the sharp decline in profitability and margins indicates significant operational challenges, making the latest results more negative than positive.

How has been the historical performance of Morepen Labs.?

Morepen Labs has shown consistent growth in net sales and profitability, with net sales increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025, and profit after tax rising from 28.84 crore to 118.02 crore in the same period. The company's total assets and liabilities also grew significantly, reflecting robust expansion.

Answer:<BR>The historical performance of Morepen Labs shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Morepen Labs has demonstrated significant growth in net sales, increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025. The total operating income followed a similar trend, reaching 1,811.58 crore in March 2025, up from 853.07 crore in March 2020. The company's operating profit (PBDIT) also improved, rising to 192.43 crore in March 2025 from 71.19 crore in March 2019. Profit before tax increased to 155.11 crore in March 2025, compared to 29.18 crore in March 2019, while profit after tax reached 118.02 crore in March 2025, up from 28.84 crore in March 2019. The company's total assets grew significantly from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, reflecting a robust expansion. Total liabilities also increased, from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, indicating a rise in borrowings and other obligations. Cash flow from operating activities showed fluctuations, with a net cash inflow of 10 crore in March 2025, following a net outflow in the previous year. Overall, Morepen Labs has shown a strong upward trend in sales and profitability, alongside an increase in total assets and liabilities over the years.

Is Morepen Labs. technically bullish or bearish?

As of November 19, 2025, Morepen Labs is in a bearish trend with moderate strength, supported by bearish MACD and moving averages, while showing mixed signals from KST and underperforming against the Sensex.

As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment.

Is Morepen Labs. overvalued or undervalued?

As of November 17, 2025, Morepen Labs is fairly valued with a PE ratio of 33.58, lower than Sun Pharma's 36.69 but higher than Cipla's 22.81, and has a low PEG ratio of 0.00, while underperforming the Sensex with a stock return of -38.87%.

As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. <BR><BR>In comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%.

Who are the top shareholders of the Morepen Labs.?

The top shareholders of Morepen Labs include Pinfold Overseas Limited with 7.03%, Scope Credits And Financial Services Pvt. Ltd. at 2.84%, and individual investors collectively holding 48.76%. There are also 44 Foreign Institutional Investors with 1.94% and no pledged promoter holdings.

The top shareholders of Morepen Labs include a mix of individual and institutional investors. The largest public shareholder is Pinfold Overseas Limited, holding 7.03%. Among the promoters, Scope Credits And Financial Services Pvt. Ltd. has the highest stake at 2.84%. Additionally, individual investors collectively hold a significant portion of 48.76%. There are also 44 Foreign Institutional Investors (FIIs) with a combined holding of 1.94%, and two mutual fund schemes that hold 0.0%. Notably, there are no pledged promoter holdings.

Has Morepen Labs. declared dividend?

No Dividend History Available